Peer-Reviewed Publications

Health technology management: the experience of a managed access approach to the reimbursement of dupilumab in Ireland.  Barrett R, Barry M, McCullagh L. Ir J Med Sci. 2023 May 9. doi: 10.1007/s11845-023-03378-7.

Clinical expert opinion to inform Health Technology Assessments. O’Callaghan J, Tilson L, Fogarty E, McCullagh L. Ir Med J; September 2023; Vol 116; No. 8; P826   Clinical expert opinion to inform Health Technology Assessment – Irish Medical Journal (imj.ie)

A comparison of relative-efficacy estimate(s) derived from both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons.  Cassidy O, Harte M, Trela-Larsen L, Walsh C, White A, McCullagh L, Leahy J., Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2023, pS1098-3015(23)03061-9 Journal Article, 2023 DOI

The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries’ past health technology assessments. Vreman RA, van Hoof D, Nachtnebel A, Daems J, van de Casteele M, Fogarty E, Adams R, Timmers L. International Journal of Technology Assessment in Health Care, 39(1), e44, 1–7  DOI

Adverse drug reactions in an ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients. Cahir C, Curran C, Walsh C, Hickey A, Brannigan R, Kirke C, Williams D, Bennett K. Front. Pharmacol., 13 (2023). https://doi.org/10.3389/fphar.2022.1029067

The effectiveness and cost of integrating pharmacists within general practice to optimize prescribing and health outcomes in primary care patients with polypharmacy: a systematic review. Croke, A., Cardwell, K., Clyne B, Moriarty F, McCullagh L, Smith S M.  BMC Prim. Care 24, 41 (2023). https://doi.org/10.1186/s12875-022-01952-z

Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting. Carey N, Leahy J, Trela-Larsen L, Mc Cullagh L & Barry M (2023)   Journal of Market Access & Health Policy, 11:1, DOI: 10.1080/20016689.2023.2166375

Neoadjuvant treatment for stage III and IV cutaneous melanoma. Gorry C, McCullagh L, O’Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Cochrane Database of Systematic Reviews 2023: Issue 1. Art. No.: CD012974. DOI: 10.1002/14651858.CD012974.pub2.

Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis. McConnell, D., Harte, M., Walsh, C., Murphy, D., Nichol, A., Barry, M. and Adams, R. Scientific Reports. 2022. DOI: https://doi.org/10.1038/s41598-022-22431-6

Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis. Carey N, Leahy J, Trela-Larsen L, McCullagh L, Barry M. International Journal of Technology Assessment in Health Care. 2022. DOI: https://doi.org/10.1017/S0266462322000356

A text-mining tool generated title-abstract screening workload savings: performance evaluation versus single-human screening. Carey N, Harte M, Mc Cullagh L. Journal of Clinical Epidemiology. 2022. DOI: https://doi.org/10.1016/j.jclinepi.2022.05.017

Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. Eichler, H., Adams, R., Andreassen, E., Arlett, P., Van de Casteele, M., Chapman, S., . . . Wenzl, M. (2021).  International Journal of Technology Assessment in Health Care, 37(1), E83. doi:10.1017/S026646232100057X

The Utility of a Rapid Review Evaluation Process to a National HTA Agency. Varley A, Tilson L, Fogarty E, McCullagh L, Barry M. PharmacoEconomics 2021. DOI: 10.1007/s40273-021-01093-8

Absence of evidence or evidence of absence – a review of the evidence for hydroxychloroquine as a potential candidate for prophylaxis against COVID-19. Cara Usher, Lea Trela-Larsen, Emer Fogarty, Aisling O’Leary, Stephen Capper, Ellen P O’Sullivan, Caitriona NiChoitir, Cathal Walsh, Michael Barry, Roisín Adams. Ann Public Health Reports 2021;5(1):160-165. DOI: 10.36959/856/513

Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2. McConnell D, Hickey C, Bargary N, Trela-Larsen L, Walsh C, Barry M, Adams R. Int. J. Environ. Res. Public Health 2021, 18, 4640. https://doi.org/10.3390/ijerph18094640

Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective. Kennedy C,  McCullagh L,  Adams R,  Trela-Larsen L, Tilson L, Barry M, Value in Health, 2021, ISSN 1098-3015, https://doi.org/10.1016/j.jval.2021.03.012. (https://www.sciencedirect.com/science/article/pii/S1098301521002096)

Integrating clinical pharmacists within general practice: protocol for a pilot cluster randomised controlled trial. Croke A, Moriarty F,  Boland F, McCullagh L, Cardwell, K, Smith , SM,   Clynee B. BMJ Open 2021;11:e041541. doi:10.1136/ bmjopen-2020-041541

Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group. Leahy J, Hickey C, McConnell D, Cassidy O, Trela-Larsen, L, Barry M, Tilson L, McCullagh L. Value in Health 2020. https://doi.org/10.1016/j.jval.2020.09.003

Evaluation of the General Practice Pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non-randomised pilot study. Cardwell K, Smith S,Clyne B, McCullagh L on behalf of the General Practice Pharmacist (GPP) Study Group, et al. BMJ Open 2020; 10: e035087. https://bmjopen.bmj.com/content/10/6/e035087.info

A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland. The European Journal of Health Economics.  Lamrock F,  McCullagh L, Tilson L,  Barry M. March 2020.   https://doi.org/10.1007/s10198-020-01181-0

The Interaction between Price Negotiations and Heterogeneity: Implications for Economic Evaluations. O’Donnell H, McCullagh L, Barry M, Walsh, C. Medical Decision Making. First Published February, 2020. https://doi.org/10.1177/0272989X19900179

Transferability of Economic Evaluations of Treatments for Advanced Melanoma. Gorry C, McCullagh L, Barry M. PharmacoEconomics (2020) 38:217–231 https://doi.org/10.1007/s40273-019-00860-y

General practitioners’ views on malnutrition management and oral nutritional supplementation prescription in the community: a qualitative study. Dominguez Castro P, Reynolds CME, Kennelly S, Clyne B, Bury G,  Hanlon D, Murrin C, McCullagh, L, Finnigan K, Clarke S, Browne S, Perrotta C, Gibney ER, Corish CA. Clinical Nutrition ESPEN. https://doi.org/10.1016/j.clnesp.2020.01.006

Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 2017.  Usher C, McCullagh L, Tilson L & Barry M. PharmacoEconomics – Open, 3, 583–589 . https://doi.org/10.1007/s41669-019-0136-1

Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review. Gorry C, McCullagh L, Barry M. Value in Health. 2019. 23. 10.1016/j.jval.2019.07.003

To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland. O’Donnell H, Lamrock L, Tilson L, Barry M. Value in Health 2019. doi.org/10.1016/j.jval.2019.06.013

Direct oral anticoagulants uptake and an oral anticoagulant paradox. Kennedy, C. Ni Choitir, C. Clarke, S. Barry, M. Bennett, K. British Journal of Clinical Pharmacology. doi: 10.1111/bcp.14171.

Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact. Joy Leahy, Howard Thom, Jeroen P. Jansen, Emma Gray, Aisling O’Leary, Arthur White, Cathal Walsh. Statistics in Medicine. 2019;1–19  https://doi.org/10.1002/sim.8139

Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines. Connolly E, O’Donnell H, Lamrock F, Tilson L, Barry M. Open (2019). doi.org/10.1007/s41669-019-00177-8

Supporting prescribing in Irish primary care: protocol for a non-randomised pilot study of a general practice pharmacist (GPP) intervention to optimise prescribing in primary care.  Cardwell K, Clyne B, Moriarty F, Wallace E, Fahey T, Boland F, McCullagh L, Clarke S, Finnigan K, Daly M, Barry M,  Smith SM (on behalf of the General Practice Pharmacist (GPP) Study Group). Pilot and Feasibility Studies 2018 4:122. https://doi.org/10.1186/s40814-018-0311-7

Neoadjuvant treatment for malignant and metastatic cutaneous melanoma.  Gorry C, McCullagh L, O’Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I.  Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No: CD012974. DOI: 10.1002/14651858.CD012974.

The incidence and healthcare costs of persistent postoperative pain following lumbar spine surgery in the UK: a cohort study using the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). Weir, S. Samnalieve, M. Tzu-Chun, K. Ni Choitir, C. Tierney, T. Taylor, R. Manca, A. Bruce, J. Cumming, D. Eldabe, S. BMJ Open 2017; 7:e017585. doi: 10.1136/bmjopen-2017-017585.

The rate of persistent post-operative pain (FBSS) in revision lumbar spinal surgery. Weir, S. Samnalieve, M. Tzu-Chun, K. Ni Choitir, C. Tierney, T. Taylor, R. Manca, A. Bruce, J. Cumming, D. Eldabe, S. The Spine Journal 2017. 17(3), pp. 10. doi: https://doi.org/10.1016/j.spinee.2016.12.030

Does instrumented spinal surgery have an increased rate of persistent post-operative pain (PPP)? Weir, S. Samnalieve, M. Tzu-Chun, K. Ni Choitir, C. Tierney, T. Taylor, R. Manca, A. Bruce, J. Cumming, D. Eldabe, S. The Spine Journal 2017. 17(3), pp. 11. doi: https://doi.org/10.1016/j.spinee.2016.12.034

Acute herpes zoster and post herpetic neuralgia in primary care: a study of diagnosis, treatment and cost. Crosbie B, Lucey S, Tilson L, Domegan L, Kieran J. Eur J Clin Microbiol Infect Dis. 2017 Dec 7. [Epub ahead of print] PMID: 29218466

Ivacaftor for cystic fibrosis; An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting. Corcoran A, Hickey N, Barry M, Usher C, McCullagh L. Irish Medical journal 2017; 110 (8): http://imj.ie/ivacaftor-for-cystic-fibrosis-an-evaluation-of-real-world-utilisation-and-expenditure-in-the-irish-healthcare-setting/

Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer. McCullagh L, Schmitz S, Barry M, Walsh C. Pharmacoeconomics. 02/08/2017 DOI: 10.1007/s40273-017-0552-y

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Mult Scler Relat Disord. 2016 Sep;9:23-30. doi: https://doi.org/10.1016/j.msard.2016.06.001

The Pharmacoeconomic Evaluation Process in Ireland. 
McCullagh L, Barry M     Pharmacoeconomics  2016-07 | journal-article.   DOI: 10.1007/s40273-016-0437-5

Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland. Susanne Schmitz, Laura McCullagh, Roisin Adams, Cathal Walsh. PharmacoEconomics March 2016, 1-13, DOI 10.1007/s40273-016-0406-z.

Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St. Vincent’s Screening To Prevent Heart Failure) Study.
Ledwidge M. T, O’Connell E, Gallagher J, Tilson L, James S, Voon V, Bermingham M, Tallon E, Watson C, O’Hanlon R, Barry M and McDonald K.  European Journal of Heart Failure, 17:672-679. doi: 10.1002/ejhf.286

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Godman B, Malmström RE, Diogene E, Gray A, Jayathissa S, Timoney A, Acurcio F, Alkan A, Brzezinska A, Bucsics A, Campbell SM, Czeczot J, de Bruyn W, Eriksson I, Yusof FA, Finlayson AE, Fürst J, Garuoliene K, Guerra Júnior A, Gulbinovič J, Jan S, Joppi R, Kalaba M, Magnisson E, McCullagh L, Miikkulainen K, Ofierska-Sujkowska G, Pedersen HB, Selke G, Sermet C, Spillane S, Supian A, Truter I, Vlahović-Palčevski V, Vien LE, Vural EH, Wale J, Władysiuk M, Zeng W, Gustafsson LL. Expert Rev Clin Pharmacol. 2015 Jan;8(1):77-94. doi: 10.1586/17512433.2015.990380.

Using the Analytic Hierarchy Process to Derive Health State Utilities From Ordinal Preference Data.
Reddy B, Kind P, Adams RC, Walsh C, Barry M. Value in Health 2014;17(7):A513. doi:/10.1016/j/jval.2014.08.1581

Health-related quality of life of patients on opiate replacement therapy.
McLaughlin J, Surah S, Synnott , Adams R, Walsh C, O’Dea S, Noone S, Keenan E, Keating S, Barry M, Bergin C, Mulcahy F, and Lyons F. Heroin Addict Relat Clin Probl 2014 (In press)

Direct and indirect economic consequences of multiple sclerosis in Ireland.
Fogarty, E; Walsh, C; McGuigan, C; Tubridy, N; Barry, M.  Applied Health Economics and Health Policy 2014;12(6):635-645 website link

The cost of the inpatient management of febrile neutropenia in cancer patients – a micro-costing study in the Irish healthcare . C. O’Brien, E. Fogarty, C. Walsh, O. Dempsey, M. Barry, M.J. Kennedy & L. McCullagh. European Journal of Cancer Care. Article first published online: 29 Jan 2014 | DOI: 10.1111/ecc.12182

Natriuretic Peptide–Based Screening and Collaborative Care for Heart Failure: The STOP-HF Randomized Trial.
Ledwidge M, Gallagher J, Conlon C, Tallon E,  O’Connell E,Dawkins I, Watson C, O’Hanlon R, Bermingham M,  Patle A, MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L; Maurer B, McDonald K.  JAMA. 2013;310(1):66-74. doi:10.1001/jama.2013.7588. website link

Health-related quality of life of HIV-infected intravenous drug users. S Surah, R Adams, L Townsend, I Reynolds, JC Kinahan, S Keating, F Mulcahy, E Keenan, M Barry and F Lyons.  International Journal of STD & AIDS: Volume 24 No 11 November 2013; 867-874.

Personalizing health care: feasibility and future implications. Godman B, Finlayson, AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J, Malmström RE, Asola E, Baumgärtel C, Bennie M, Bishop I, Bucsics A, Campbell S, Diogene E, Ferrario A, Fürst J, Garuoliene K, Gomes M, Harris K, Haycox A, Herholz H, Hviding K, Jan S, Kalaba M, Kvalheim C, Laius O, Lööv SA, Malinowska K, Martin A, McCullagh L et al.  BMC Medicine doi:10.1186/1741-7015-11-179. 2013, 11(1):179 website link

Using resource modelling to inform decision making and service planning:  the case of colorectal cancer screening in Ireland.
Sharpe L, Tilson L, Whyte S, O Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M, Comber H.  BMC Health Services Research 2013, 13:105 doi:10.1186/1472-6963-13-105 website link

Incorporating data from various trial designs into a mixed treatment comparison model.
Schmitz S, Adams R, Walsh C. Statistics in Medicine.  Article first published online: 25 FEB 2013. DOI:10.1002/sim.5764

Relating Health-related Quality of Life to Disability Progression in Multiple Sclerosis using the Five-level EQ-5D.
Fogarty E, Walsh C, Adams R, McGuigan C, Barry M, Tubridy N.  Multiple Sclerosis 2013;19(9):1190-1196 website link

A reference pricing system for Ireland. Usher C, Barry M, Expert Review of Pharmacoeconomics and Outcomes Research.  2012;12(6):675-677.

The use of continuous data versus binary data in MTC models:  A case study in rheumatoid arthritis.  Schmitz S, Adams R, Walsh C, BMC Medical Research Methodology 2012; 12:167.

The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of HCV Genotype 1.
Jennifer K, Schmitz S, O’Leary A, Walsh C, Bergin C, Norris S, Barry M.  Clinical Infectious Diseases. First published online: October 16, 2012

Prescribing trends for dabigatran etexilate in primary care.
McCullagh L and Barry M.Irish Medical Journal 2012; 105 (5): 34-136.

Value-of-Information Analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish Healthcare Setting.
McCullagh L, Walsh C, Barry, M.  Pharmacoeconomics 2012; 30(10):941-959.

The Clinical and Economic Burden of Poor Adherence and Persistence with Osteoporosis Medications in Ireland
Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster J-Y. Value in Health.  2012 Jul-Aug;15(5):604-12.

Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.
L Sharp, L Tilson, S Whyte, A O’Ceilleachair, C Walsh, C Usher, P Tappenden, J Chilcott, A Staines, M Barry and H Comber. Br J Cancer. 2012:106; 805-816.

Cost containment interventions introduced on the Community Drugs Schemes in Ireland-Evaluation of Expenditure Trends Using a National Prescription Claims Database.
C. Usher, L. Tilson, K. Bennett, M. Barry. Clinical Therapeutics 2012, 34(3):632-639. website link

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a bayesian approach.
Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O.  Ann Rheum Dis. 2012 Feb;71(2):225-30. website link

Cost of care of colorectal cancer in Ireland: a health care payer perspective.
Tilson L, Sharp L, Usher C et al. Eur J Health Econ. 2012 Aug;13(4):511-24.

Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
Tilson L, Jit M, Schmitz S, et al.  Vaccine 2011; 29 (43): 7463-7473. website link

The Impact of a Revised EQ-5D Population Scoring on Preference-Based Utility Scores in an Inflammatory Arthritis Cohort.
Adams R, Craig BM, Walsh CD, Veale DJ, Bresnihan B, Fitzgerald O, Barry M.  Value in Health 2011;14(6):921-927.

Does Model Choice in Mixed Treatment Comparisons Affect the Decision in Economic Evaluations?
Adams R, Schmitz S, Fitzgerald O, Walsh C, Barry M.  ISPOR Connections. 2011. Vol.17. No.2.

Recent developments in pharmacoeconomic evaluation in Ireland
Lesley Tilson, Michael Barry. Expert Review of Pharmacoeconomics & Outcomes Research, June 2010, Vol. 10, No.3, Pages 221-224

Public drug expenditure in the Republic of Ireland
Michael Barry, Cara Usher, Lesley Tilson.  Expert Review of Pharmacoeconomics & Outcomes Research, June 2010, Vol. 10, No. 3, Pages 239-245

Reimbursement of new high cost drugs – Funding the unfundable?
Barry M, Tilson L. IMJ May 2010; 103 (5): 133

Understanding the Relationship between EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis.
Adams Roisin, Walsh Cathal, Veale Douglas, Bresnihan Barry, Fitzgerald Oliver, Barry Michael. Pharmacoeconomics 2010;28(6):477-487

Pharmacoeconomic Evaluation in Ireland: A Review of the Process
Tilson L, O’Leary A, Usher C, Barry M. Pharmacoeconomics 2010;28(4): 307-322.

Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations.
Hughes DA, Tilson L, Drummond M. Pharmacoeconomics 2009;27(8):635-43.

A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Knee Replacement in the Irish Health Care Setting
McCullagh L, Tilson L, Walsh C, Barry M. Pharmacoeconomics 2009;27(10):829-846

Drug expenditure in Ireland 1997 – 2007.
M Barry, D Molloy, C Usher, L Tilson. IMJ Dec 2008. Vol. 101; No 10: 299 – 302.

Cost effectiveness of HPV vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 & 18 using a transmission dynamic model.
Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M. Vaccine 2008 Oct 16;26(44):5654-61.

Cost effectiveness of treatments reducing coronary heart disease mortality in Ireland 2000 to 2010.

Bennett K, Kabir Z, Barry M, Tilson L, Fidan D, Capewell S. Value in Health January/February 2009 Volume 12 Issue 1.

The cost effectiveness of cotrimoxazole prophylaxis in HIV infected children in Zambia.
Ryan M, Griffin S, Chitah B, Walker A, Mulenga V, Kalola D, Hawkins N, Merry C, Barry M, Chintu C, Sculpher M, Gibb D. AIDS 2008; 22 (6): 749-757. website link

The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis.
McGowan B, Bennett K, Barry M, Canny M. IMJ 2008; 101 (2): 38-41.

Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland.
Tilson L, Usher C, Butler K, Fitzsimons J, O’Hare F, Cotter S, O’Flanagan D, Johnson H, Barry M.  Value in Health. 2008;11(5):898-903.

Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation
Lesley Tilson, Lelia Thornton, Darina O’Flanagan, Howard Johnson, Michael Barry.  European Journal of Public Health. Jun 2008;18(3):275-82.

Recent developments in pricing and reimbursement of medicines in Ireland
Michael Barry & Lesley Tilson. Expert Rev. Pharmacoeconomics Outcomes Res. 7(6), 605 – 611 (2007).

Best practice for Helicobacter Pylori Eradication in the primary care setting
Walshe V, O’Morain C, Bennett K, Keeling PWN, Barry M. IMJ June 2006; vol 99 (1): 11-12

Cost effectiveness of statin therapy for the primary prevention of coronary heart disease
Walshe V, Nash A, Barry M. IMJ. 2006: 99 (5): 144-145

The rising cost of glaucoma drugs in Ireland 1996 – 2003
FA Knox, M Barry, B McGowan, C O’Brien. Br J Ophthalmol 2006,.90: 162-165.

The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland
Lesley Tilson, Kathleen Bennett, Michael Barry.Eur J Health Economics Sep 2005 Vol 6 Issue 3. 267-273

European Pharmaceutical Pricing and Reimbursement Strategies (2005)
Lesley Tilson & Michael Barry.  To order a copy of this publication please contact the NCPE by phone (01 4103427) or email ([email protected]).

Cost Effective Prescribing of Proton Pump Inhibitors (PPI’s) in the GMS Scheme
B McGowan, K Bennett, L Tilson, M Barry. IMJ March 2005 Vol. 98 No. 3, 78 – 80

Prescribing trends for Nicotine Replacement Therapy in Primary Care
L Tilson, K Bennett, M Barry. IMJ Oct 2004 Vol 97 No. 9, 270-273

The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
Lesley Tilson, Bernadette McGowan, Kathleen Bennett and Michael Barry.Eur J Health Economics 2004.

Population Based Study of the Cost of Inpatient Care for HIV Infected Individuals in an Irish Teaching Hospital
M Ryan, C Merry, C Ryan, K Bennett, A Heerey, B McGowan, F Mulcahy, M Barry.IMJ July/August 2004 Vol 97 No 7.200-202

Patient Co-payment for Prescription Medicines Across Europe – How do we compare
M Barry, L Tilson, M Ryan IMJ March 2004:97(3):69-70.

Pricing and reimbursement of drugs in Ireland
Michael Barry, Lesley Tilson, Mairin Ryan. Eur J Health Economics. Vol 5 no.2, 2004.190 – 194.

Cost of treating Stroke in an Irish teaching hospital
B McGowan, A Heerey, L Tilson, M Ryan, M Barry. IMJ Sept 2003;96(8):234-236.

Generic Drug Utilisation on the General Medical Services Scheme in 2001
Tilson L, McGowan B, Ryan M, Barry M. IMJ June 2003;96(6):176-179.

Cost-Effectiveness of Spironolactone in Patients with Severe Heart Failure
Tilson L, McGowan B, Ryan M, Barry M. IJMS 2003;172(2):70-72. Download Document

Decision-making by healthcare payers
M Levine, R Taylor, M Ryan, M Sculpher. Respiratory Medicine August 2002 Vol. 96 (Suppl C) S3-S10.

Cost-Effectiveness of Beta Blocker Therapy for Patients with Chronic Severe Heart Failure in Ireland
M Barry. IMJ June 2002;95(6):174-177. Download Document

Cost-Effectiveness of Statins for the Secondary Prevention of Coronary Heart Disease in Ireland

M Barry, A Heerey. IMJ May 2002;(95):133-135

Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation
A Heerey, B McGowan, M Ryan, M Barry, Expert Rev. Pharmacoeconomics Outcomes Res. 2(1), 29-33 (2002) Download Document

Cost of treating Heart Failure in an Irish teaching hospital
B McGowan, A Heerey, M Ryan, M Barry. IJMS 2001;169(4):241-244. Download Document

The potential for drug interactions with statin therapy in Ireland
A Heerey, M Barry, M Ryan, A Kelly. IJMS 2001;169(3):176-179. Download Document

Cost of treating acute myocardial infarction in an Irish teaching hospital
A Heerey, B McGowan, M Ryan, J Feely, M Walsh, M Barry. IMJ 2001;94(5):144-146. Download Document

Alternative approaches to the economic evaluation of a drug for patients with Alzheimers Disease.
D McCulloch, A Heerey, M Ryan, M Barry. EHP 2000;6(2):64-68. Download Document

Drug Reimbursement in Ireland
M Barry, A Heerey, J Feely. IMJ 2000;93(3):71-72. Download Document

The Scientific evaluation of Drugs – Pharmacoeconomics Applied
M Barry, J Feely, D McCulloch. IPJ 2000;78(2):66-69

Pharmacoeconomics in Ireland – concepts and terminology
M Barry, J Feely. IJMS 2000;169(1);63-64. Download Document

Pharmacoeconomics of lipid lowering therapy in Ireland
M. Barry, A Heerey, O Sheehan, M Ryan, D McCulloch, J Feely. IMJ 1999;92; 7; 430-432

The Irish National Centre for Pharmacoeconomics: Its Rationale and Role
M Barry, A Heerey, D McCulloch, M Ryan, C Merry, C Hughes, J Feely. IMJ 1999;92(4):337-339.